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Case Description
A 43-year-old man from a rural area in Brazil presented to
his physician with complaints of palpitations and lightheaded-
ness, mainly on exertion. An electrocardiogram (ECG) showed
right bundle-branch block (RBBB), left anterior fascicular block
(LAFB), and a premature ventricular contraction (PVC)
(Figure 1A). Echocardiography revealed a mildly depressed
left ventricular (LV) ejection fraction (EF) of 46%, a slightly
increased LV end-diastolic diameter (60 mm), and a LV apical
aneurysm (Figure 1B and 1C). Subsequent 24-hour ambulatory
ECG monitoring (Holter) recorded 4,055 isolated polymorphic
PVCs, 236 couplets, and 17 short runs of nonsustained
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Figure 1. Patient characteristics. (A) 12-lead ECG showing the three most frequent abnormalities in Chagas heart disease: right bundle branch
block, left anterior fascicular block, and a premature ventricular contraction (lead V3). (B) Transthoracic echocardiogram recorded at the four chamber
apical view showing slightly diminished left ventricular systolic function and mildly dilated left ventricle. (C) Two chamber apical view showing more
clearly a characteristic digitiform left ventricular apical aneurysm (arrow).
doi:10.1371/journal.pntd.0000852.g001
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several episodes of NSVT (Figure 2A). The patient was initially
treated with an angiotensin-converting enzyme (ACE) inhibitor
and amiodarone (loading dose of 600 mg/day for 1 week,
followed by 300 mg/day). One month later, Holter and
exercise testing were repeated, showing a significant reduction
in total PVCs on Holter, but with persistence of few episodes of
NSVT on exercise testing. The dose of amiodarone was
increased to 400 mg/day, both tests were repeated, and
abolition of NSVT was then obtained (Figure 2B).
Figure 2. Exercise testing performed and recorded during the last hour of Holter monitoring. (A) Control exercise showing frequent
premature ventricular complexes, couplets, and short runs of nonsustained ventricular tachycardia. (B) Exercise testing after administration of
amiodarone (400 mg/day), showing a significant reduction in the number of premature ventricular complexes and couplets, and a complete
abolition of episodes of nonsustained ventricular tachycardia.
doi:10.1371/journal.pntd.0000852.g002
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Chagas heart disease (chronic chagasic cardiomyopa-
thy). Chagas heart disease (CHD) is the most common etiology of
cardiomyopathy in Latin America, and a major cause of
cardiovascular death among middle-aged individuals in endemic
areas. CHD is also the most serious and frequent manifestation of
chronic Chagas disease. It develops in 20%–30% of infected
persons, usually 10–30 years after Trypanosoma cruzi contamination,
and manifests as three major syndromes that often coexist in the
samepatient: arrhythmias, heart failure, and thromboembolism [1].
Arrhythmias are very common, of different types, and may
cause palpitations, dizziness, syncope, and sudden cardiac death
(SCD). Frequent, complex PVCs, including couplets and runs of
NSVT, are a common finding on 24-h Holter monitoring and
exercise testing. They correlate with the severity of ventricular
dysfunction, but can also occur in patients with quite well
preserved ventricular function. Episodes of NSVT are seen in
approximately 40% of patients with mild wall motion abnormal-
ities and in virtually all patients with heart failure, an incidence
that is higher than that observed in other cardiomyopathies [2].
Heart failure is often a late manifestation of CHD. It is usually
biventricular with a predominance of left-sided failure at initial
stages and of right-sided failure at more advanced disease.
Systemic and pulmonary embolisms arising from mural thrombi
in the cardiac chambers are quite frequent. Clinically, the brain is
by far the most frequently recognized site of embolisms (followed
by limbs and lungs), but at necropsy, embolisms are found more
frequently in the lungs, kidneys, and spleen [3]. SCD is the main
cause of death in patients with CHD, accounting for nearly two-
thirds of all deaths, followed by refractory heart failure (25%–30%)
and thromboembolism (10%–15%) [4].
Electrocardiographic alterations are varied, but the most
common are RBBB, LAFB, PVCs, primary ST-T changes, Q
waves, low QRS voltage, different degrees of atrioventricular block,
and manifestations of sinus node dysfunction. All these alterations
may be isolated or associated. The association of RBBB with LAFB
strongly suggests chronic CHD in endemic regions [1,5].
On the chest radiography, cardiac size is normal in the initial
stages of disease and even when multiple ECG abnormalities are
present. The cardiac size may be slightly, moderately, or severely
increased at later stages of CHD. In nearly half of the cases with
heart failure, the manifestations of pulmonary congestion are poor
or even absent [1,5]. The echodopplercardiogram may be
abnormal even in patients with nonspecific ECG alterations and
normal chest radiography. Echo shows wall motion abnormalities
in two main areas of LV: the apex and the posterior-inferior wall.
The most characteristic findings are apical aneurysms (with or
without thrombi) [1,5]. Three types of aneurysms have been
described: digitiform (the most common), mammilar, and saccular.
More advanced disease is characterized by global ventricular
dilatation and diffuse hypokinesis, often associated with mitral and
tricuspid regurgitation [1,5].
Holter monitoring is an excellent method for investigating
patients with CHD. It may be used to identify complex ventricular
arrhythmias, diagnose transitory arrhythmias, and evaluate anti-
arrhythmic therapy. The exercise testing evaluates the functional
capacity of the patient, qualifies and quantifies PVCs, and may
verify the efficacy of anti-arrhythmic drugs.
In patients with high suspicion of chronic Chagas disease or in
those with a compatible clinical syndrome, because parasitaemia is
scarce, the presence of immunoglobulin G (IgG) antibodies against
T. cruzi antigens needs to be detected by at least two different
serological methods (usually enzyme-linked immunosorbent assay,
indirect immunofluorescence, or indirect haemagglutination) to
confirm the etiological diagnosis.
The initial evaluation of the newly diagnosed patient with
chronic T. cruzi infection includes a complete medical history and
physical examination, and a resting ECG [1,5,6]. Patients with
ECG changes consistent with CHD should undergo a routine
cardiac evaluation, including ambulatory 24-h Holter monitoring
(complemented with an exercise testing whenever possible) to
detect arrhythmias and assess functional capacity; chest radiogra-
phy and echocardiography to refine the assessment of cardiac size
and function, and to incorporate additional prognostic informa-
tion; and other cardiologic tests as indicated. From the results of
these tests, clinicians can stratify individual patients by risk and
implement appropriate treatment [1,5,6].
Recently, some of us used a rigorous multivariate analysis to
develop a risk score for mortality prediction in 424 outpatients with
CHD from a regional Brazilian cohort [7]. Several demographic,
clinical, and noninvasive variables were tested, and six were
identified as independent predictors of mortality and were assigned
points according to the strength of their statistical association with
the outcome: New York Heart Association (NYHA) class III or IV
(5 points), cardiomegaly (5 points), LV systolic dysfunction on
echocardiography (3 points), NSVT on Holter (3 points), low QRS
voltage (2 points), and male gender (2 points). From addition of the
points to provide the risk score, patients were classified into groups
of low (0–6 points), intermediate (7–11 points), and high risk (12–
20 points), with corresponding 10-year mortality rates of 10%,
44%, and 84%, respectively [7].
The clinical history, the ECG abnormalities, and the findings on
echo, Holter, and exercise testing in the present case are
characteristic of chronic CHD. Serological tests for Chagas disease
were performed and gave positive results. According to the scoring
system to determine the risk of death described above, this patient
would receive a score of 8 points based on his sex (2 points), the
presence of apical aneurysm (3 points), and the presence of runs of
NSVT (3 points). This score puts him in the intermediate-risk
category (risk of death in the next 10 years of 44%).
The importance of having the results of a chest radiography on
board, which was not done in this case, relies on the fact that the
presence of cardiomegaly would add 5 more points to the patient’s
risk score, moving him to a higher-risk category. Of note, the
combination of NSVT and LV systolic dysfunction in patients with
CHD increase the risk of subsequent death by 15 times compared
to patients without these abnormalities on Holter monitoring and
on echocardiography [8].
Management of patients with CHD should focus on eradication
of the parasite, which may halt disease progression, alleviation of
symptoms of disease, and identification of patients at high risk of
death, in order to implement strategies with the potential to reduce
mortality. Regarding antitrypanosomal treatment, only two agents
are currently available: benznidazole and nifurtimox. On the basis
of the results of some observational studies, a panel of experts
convened by the US Centers for Disease Control and Prevention
in 2006 recommended that antiparasitic therapy should generally
be offered to adults 19–50 years of age with mild to moderate
cardiomyopathy [6]. A multicenter randomized controlled trial is
currently under way to assess whether trypanocidal therapy affects
mortality and cardiovascular outcomes in 3,000 patients aged 18–
75 years with chronic CHD without advanced cardiac involve-
ment, but results will not be available until 2012 at the earliest [9].
Regarding antiarrhythmic therapy, despite a scarcity of data,
individuals at high risk of SCD such as the patient in this vignette,
are usually treated with amiodarone. Amiodarone markedly
reduces the frequency and complexity of ventricular arrhythmias
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randomized trials that included chagasics patients (EPAMSA
[10] and GESICA [11]). The efficacy of amiodarone was
evaluated by a noninvasive approach, which uses repeated
ambulatory monitoring and exercise testing [12]. Criteria for
drug efficacy depend upon the suppression of spontaneously
occurring arrhythmias. Support for the use of this approach is
based on the observation that the presence of runs of NSVT
significantly increases the risk of death. Moreover, their prevention
with amiodarone may improve survival [12].
Because some evidence suggests that mild segmental LV wall
motion abnormalities are predictors of deterioration of ventricular
function during follow-up [13], the use of an ACE inhibitor is also
highly recommended. Finally, whether administration of a
betablocker (to prevent further myocardial damage and death)
and either aspirin or warfarin (to prevent thromboembolism)
should be considered for this patient remains an open and
challenging question.
The ethics committee of Anis Rassi Hospital approved this
report and waived the need for informed consent.
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Key Learning Points
N Clinical manifestations of Chagas heart disease are diverse and related to three major syndromes: cardiac arrhythmias, heart
failure, and thromboembolism. Improved models for risk stratification are now available, and certain guided treatments
may increase survival.
N Segmental or global left ventricular dysfunction and episodes of nonsustained ventricular tachycardia are independent,
additive risk factors for overall mortality in Chagas cardiomyopathy.
N Although not supported by incontestable evidence, it is possible that patients with runs of nonsustained ventricular
tachycardia on Holter/exercise testing, and asymptomatic or mildly symptomatic left ventricular dysfunction on
echocardiography, derive some benefit from combined therapy with an angiotensin-converting enzyme inhibitor and
amiodarone.
N Persistence of parasites and the accompanying chronic inflammation is the basis for the pathology in Chagas heart disease.
Thus, unless proved otherwise by a randomized controlled trial, benznidazole or nifurtimox should usually be offered to
patients ,50 years old with presumably long-standing indeterminate T. cruzi infections or even with mild to moderate
disease.
N The potential benefits of novel therapies (e.g., betablockers, implantable cardioverter defibrillators) need assessment in
prospective randomized trials. The best therapeutic strategy for patients with apical aneurysm not containing thrombus is
unknown.
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